Drug Safety

, Volume 24, Issue 15, pp 1127–1142 | Cite as

A Benefit-Risk Assessment of Caffeine as an Analgesic Adjuvant

Review Article

Abstract

Caffeine has been an additive in analgesics for many years. However, the analgesic adjuvant effects of caffeine have not been seriously investigated since a pooled analysis conducted in 1984 showed that caffeine reduces the amount of paracetamol (acetaminophen) necessary for the same effect by approximately 40%. In vitro and in vivo pharmacological research has provided some evidence that caffeine can have anti-nociceptive actions through blockade of adenosine receptors, inhibition of cyclo-oxygenase-2 enzyme synthesis, or by changes in emotion state. Nevertheless, these actions are only considered in some cases. It is suggested that the actual doses of analgesics and caffeine used can influence the analgesic adjuvant effects of caffeine, and doses that are either too low or too high lead to no analgesic enhancement.

Clinical trials suggest that caffeine in doses of more than 65mg may be useful for enhancement of analgesia. However, except for in headache pain, the benefits are equivocal. While adding caffeine to analgesics increases the number of patients who become free from headache [rate ratio = 1.36,95% confidence interval (CI) 1.17 to 1.58], it also leads to more patients with nervousness and dizziness (relative risk = 1.60, 95% CI 1.26 to 2.03).

It is suggested that long-term use or overuse of analgesic medications is associated with rebound headache. However, there is no robust evidence that headache after use or withdrawal of caffeine-containing analgesics is more frequent than after other analgesics. Case-control studies have shown that caffeine-containing analgesics are associated with analgesic nephropathy (odds ratio = 4.9, 95% CI 2.3 to 10.3). However, no specific contribution of caffeine to analgesic nephropathy can be identified from these studies. Whether caffeine produces nephrotoxicity on its own, or increases nephrotoxicity due to analgesics, is yet to be established.

References

  1. 1.
    Arnaud MJ. The pharmacology of caffeine. Prog Drug Res 1987; 31: 273–313PubMedGoogle Scholar
  2. 2.
    Currier RD, Westerberg MR. Evaluation of a salicylamide compound in the treatment of headache. Univ Mich Med Bull 1958; 24: 415–8PubMedGoogle Scholar
  3. 3.
    Marrs JW, Glass WW, Silvani J. Report of an investigation of D-propoxyphene hydrochloride. Am J Pharm 1959; 131: 271–6PubMedGoogle Scholar
  4. 4.
    Cass LJ, Frederick WS. The augmentation of analgesic effect of aspirin with phenacetin and caffeine. Curr Ther Res 1962; 4: 583–8PubMedGoogle Scholar
  5. 5.
    Moertel CG, Ahmann DL, Taylor WF, et al. Relief of pain by oral medications: a controlled evaluation of analgesic combinations. JAMA 1974; 229: 55–9PubMedCrossRefGoogle Scholar
  6. 6.
    Laska EM, Sunshine A, Zighelbolm I, et al. Effect of caffeine on acetaminophen analgesia. Clin Pharmacol Ther 1983; 33: 498–509PubMedCrossRefGoogle Scholar
  7. 7.
    Laska EM, Sunshine A, Mueller F, et al. Caffeine as an analgesic adjuvant. JAMA 1984; 25: 1711–8CrossRefGoogle Scholar
  8. 8.
    Sunshine A, Laska E, Siegel C, et al. Analgesic adjuvancy of caffeine with ibuprofen in 3 different postpartum pain populations [abstract]. Clin Pharmacol Ther 1989; 45(2): 174Google Scholar
  9. 9.
    Schachtel BP, Thoden WR, Konerman JP, et al. Headache pain model for assessing and comparing the efficacy of over-the-counter analgesic agents. Clin Pharmacol Ther 1991; 50: 322–9PubMedCrossRefGoogle Scholar
  10. 10.
    Migliardi JR, Armellino JJ, Friedman M, et al. Caffeine as an analgesic adjuvant in tension headache. Clin Pharmacol Ther 1994; 56(5): 576–86PubMedCrossRefGoogle Scholar
  11. 11.
    Diamond S, Balm TK, Freitag FG. Ibuprofen plus caffeine in the treatment of tension-type headache. Clin Pharmacol Ther 2000; 68: 312–9PubMedCrossRefGoogle Scholar
  12. 12.
    Jain AK, Mcmahon FG, Ryan JR, et al. A double-blind-study of ibuprofen 200 mg in combination with caffeine 100 mg, ibuprofen 400 mg, and placebo in episiotomy pain. Curr Ther Res Clin Exp 1988; 43(4): 762–9Google Scholar
  13. 13.
    Ward N, Whiteny C, Avery D, et al. The analgesic effects of caffeine in headache. Pain 1991; 44: 151–5PubMedCrossRefGoogle Scholar
  14. 14.
    Zhang WY, Li Wan Po A. Analgesic efficacy of paracetamol and its combination with codeine and caffeine in surgical pain: a meta-analysis. J Clin Pharm Ther 1996; 21(4): 261–82PubMedCrossRefGoogle Scholar
  15. 15.
    Zhang WY, Po AL. Do codeine and caffeine enhance the analgesic effect of aspirin? A systematic overview. J Clin Pharm Ther 1997; 22(2): 79–97PubMedCrossRefGoogle Scholar
  16. 16.
    Li Wan Po A, Zhang WY. Analgesic efficacy of ibuprofen and of its combination with codeine or caffeine in postsurgic pain. Eur J Clin Pharmacol 1998; 53: 303–11CrossRefGoogle Scholar
  17. 17.
    Sawynok J. Pharmacological rationale for clinical use of caffeine. Drags 1995; 49: 37–50CrossRefGoogle Scholar
  18. 18.
    Baumgartner C, Wesseley P, Bingol C, et al. Long-term prognosis of analgesic withdrawal in patients with drug-induced headache. Headache 1989; 29: 510–4PubMedCrossRefGoogle Scholar
  19. 19.
    Diener HC, Gerber WD, Geiselhart S, et al. Short and long-term effects of withdrawal in drag-induced headache. In: Diener HC, Wilkinson M, editors. Drag-induced headache. Berlin Heidelberg: Springer-Verlag 1988: 133–42CrossRefGoogle Scholar
  20. 20.
    Micieli G, Manzoni GC, Granella F, et al. Clinical and epidemiological observations on drag abuse in headache patients. In: Diener HC, Wilkinson M, editors. Drug-induced headache. Berlin Heidelberg: Springer-Verlag, 1988: 20–8CrossRefGoogle Scholar
  21. 21.
    De Broe ME, Elseviers MM. Analgesic nephropathy. N Engl J Med 1998; 338: 446–52PubMedCrossRefGoogle Scholar
  22. 22.
    Delzell E, Shapiro S. A review of epidemiological studies of nonnarcotic analgesics and chronic renal disease. Medicine 1998; 77: 102–21PubMedCrossRefGoogle Scholar
  23. 23.
    Debas HT, Cohen MM, Holubitsky IB, et al. Caffeine stimulated gastric acid and pepsin secretion dose-response studies. Scand J Gastroenterol 1971; 6: 453–7PubMedCrossRefGoogle Scholar
  24. 24.
    Onrot J, Shaheen O, Biaggione I, et al. Reduction of liver plasma flow by caffeine and theophylline. Clin Pharmacol Ther 1986; 40: 506–10PubMedCrossRefGoogle Scholar
  25. 25.
    Sawynok J, Yaksh TL. Caffeine as an analgesic adjuvant: a review of pharmacology and mechanisms of action. Pharmacol Rev 1993; 45: 43–85PubMedGoogle Scholar
  26. 26.
    Aguirre-Bafiuelos P, Castañeda-Hernández G, López-Muñoz FJ, et al. Effect of coadministration of caffeine and either adenosine agonists or cyclic nucleotides on ketorolac analgesia. Eur J Pharmacol 1999; 377: 175–82CrossRefGoogle Scholar
  27. 27.
    Castafieda-Hernández G, Castillo-Méndez MS, López-Muñoz FJ, et al. Potentiation by caffeine of the analgesic effect of aspirin in the pain-induced functional impairment model in the rat. Can J Physiol Pharmacol 1994; 72: 1127–31CrossRefGoogle Scholar
  28. 28.
    Engelhardt G, Mauz AB, Pairet M. Role of caffeine in combined analgesic drugs from the point of view of experimental pharmacology. Arzneimittelforschung 1997; 47: 917–27PubMedGoogle Scholar
  29. 29.
    Flores-Acevedo DM, Flores-Murrieta FJ, Castañeda-Hernández G, et al. Potentiation of the analgesic effect of tolmetin, a potent non-steroidal anti-inflammatory drag by caffeine in the rat. Pharm Sci 1995; 1: 441–4Google Scholar
  30. 30.
    Granados-Soto V, López-Muñoz FJ, Castañeda-Hernández G, et al. Characterization of the analgesic effects of paracetamol and caffeine in the pain-induced functional impairment model in the rat. J Pharm Pharmacol 1993; 45: 627–31PubMedCrossRefGoogle Scholar
  31. 31.
    Seegers AJM, Oiling M, Jager LP, et al. The anti-inflammatory, analgesic and antipyretic activities of non-narcotic analgesic drag mixtures in rats. Arch Int Pharmacodyn 1980; 251: 237–54Google Scholar
  32. 32.
    Siegers CP. Effects of caffeine on the absorption and analgesic effect of paracetamol in rats. Pharmacology 1973; 10: 19–27PubMedCrossRefGoogle Scholar
  33. 33.
    Daly JW. Mechanism of action of caffeine. In: Garattini S, editor. Caffeine, coffee, and health. New York (NY): Raven Press, 1993: 97–150Google Scholar
  34. 34.
    Fiebich BL, Lieb K, Hull M, et al. Effects of caffeine and paracetamol alone or in combination with acetysalicylic acid on prostaglandin E2 synthesis in rat microglial cells. Neuropharmacology 2000; 39: 2205–13PubMedCrossRefGoogle Scholar
  35. 35.
    Luong C, Miller A, Barnett J, et al. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nature Struct Biol 1996; 3: 927–33PubMedCrossRefGoogle Scholar
  36. 36.
    Fiebich BL, Biber K, Lieb K, et al. Cyclooxygenase-2 expression in rat microglia is induced by adenosine A2a-receptors. Glia 1996; 18: 152–60PubMedCrossRefGoogle Scholar
  37. 37.
    Ghelardini C, Galeotti N, Bartolini A. Caffeine induces central cholinergic analgesia. Naunyn-Schmiedebergs Arch Pharmacol 1997; 356(5): 590–5PubMedCrossRefGoogle Scholar
  38. 38.
    Craig K. Emotional aspects of pain. In: Wall P, Melzack R, editors. Textbook of pain. Edinburgh: Churchill Livingstone, 1989: 220–30Google Scholar
  39. 39.
    Granados-Soto V, Castaneda-Hernandez G. A review of thepharmacokinetic and pharmacodynamic factors in the potentiation of the antinociceptive effect of nonsteroidal anti-inflammatory drugs by caffeine. J Pharmacol Toxicol Methods 1999; 42: 67–72PubMedCrossRefGoogle Scholar
  40. 40.
    Wojicki J, Samochoviec L, Lawezynski L, et al. A double-blind comparative evaluation of aspirin, paracetamol and paracetamol and caffeine (Finimal) for their analgesic effectiveness. Arch Immunol Ther Exp 1977; 25: 175–9Google Scholar
  41. 41.
    DeKornfeld TJ, Lasagna L, Frazier TM. A comparative study of five proprietary analgesic compounds. JAMA 1962; 182: 1315–8PubMedCrossRefGoogle Scholar
  42. 42.
    Bauer RO, Baptista Jr A, Gruber Jr CM. Evaluation of propoxyphene napsylate compound in post partum uterine cramping. J Med 1974; 5: 317–28PubMedGoogle Scholar
  43. 43.
    Jain AK, McMahon FG, Ryan JR, et al. Aspirin and caffeine in postpartum pain relief. Clin Pharmacol Ther 1978; 24: 69–75PubMedGoogle Scholar
  44. 44.
    Rubin A, Winter Jr L. A double-blind randomized study of an aspirin/caffeine combination versus acetaminophen/aspirin combination versus acetaminophen versus placebo in patients with moderate to severe post-partum pain. J Int Med Res 1984; 12(6): 338–45PubMedGoogle Scholar
  45. 45.
    Finney DJ. Statistical methods in biological assay. 3rd ed. New York (NY): Macmillan Publishing Co. Inc., 1979Google Scholar
  46. 46.
    Forbes JA, Beaver WT, Jones KF, et al. Effect of caffeine on ibuprofen analgesia in postoperative oral-surgery pain. Clin Pharmacol Ther 1991; 49(6): 674–84PubMedCrossRefGoogle Scholar
  47. 47.
    Laska E, Gormley M, Sunshine A, et al. A bioassay computer program for analgesic clinical trials. Clin Pharmacol Ther 1967; 8: 658–69PubMedGoogle Scholar
  48. 48.
    Winter L, Appleby F, Ciccone P, et al. A double-blind, comparative evaluation of acetaminophen, caffeine, and the combination of acetaminophen and caffeine in outpatients with postoperative oral surgery pain. Curr Ther Res 1983;33: 115–22Google Scholar
  49. 49.
    Forbes JA, Jones KF, Kehm CJ, et al. Evaluation of aspirin, caffeine, and their combination in postoperative oral surgery pain. Pharmacotherapy 1990; 10(6): 387–93PubMedGoogle Scholar
  50. 50.
    McQuay HJ, Angell K, Carroll D, et al. Ibuprofen compared with ibuprofen plus caffeine after third molar surgery. Pain 1996; 66: 247–51PubMedCrossRefGoogle Scholar
  51. 51.
    Wallenstein SL. Analgesic studies of aspirin in cancer patients. In: Dale TLC, editor. Proceedings of the Aspirin Symposium. London: The Aspirin Foundation, 1975: 5–10Google Scholar
  52. 52.
    Schachtel BP, Filligan JM, Lane AC, et al. A double-blind study comparing aspirin with caffeine to aspirin and placebo in patients with sore throat. Arch Int Med 1991; 151: 733–9CrossRefGoogle Scholar
  53. 53.
    Elwyn G, Edwards A, Gwyn R, et al. Towards a feasible model for shared decision making: focus group study with general practice registrars. BMJ 1999; 319: 753–6PubMedCrossRefGoogle Scholar
  54. 54.
    Feinstein AR, Heinemann LAJ, Dalessio D, et al. Do caffeinecontaining analgesics promote dependence? A review and evaluation. Clin Pharmacol Ther 2000; 68(5): 457–67PubMedCrossRefGoogle Scholar
  55. 55.
    Michielsen P, De Schepper PD, et al. Analgesic nepropathy. N Engl J Med 1998; 339: 48–50PubMedGoogle Scholar
  56. 56.
    McCredie M, Stewart JH, Mahony JF. Is phenacetin responsible for analgesic nephropathy in New South Wales? Clin Nephrol 1982; 17(3): 134–40PubMedGoogle Scholar
  57. 57.
    McCredie MM, Stewart JH. Does paracetamol cause urothelial cancer or renal papillary necrosis? Nepron 1988; 49: 296–300Google Scholar
  58. 58.
    Murray TG, Stolley PD, Anthony JC, et al. Epidemiologic study of regular analgesic use and end-stage renal disease. Arch Intern Med 1983; 143(9): 1687–93PubMedCrossRefGoogle Scholar
  59. 59.
    Sandier DP, Smith JC, Weinberg CR, et al. Analgesic use and chronic renal disease [see comments]. N Engl J Med 1989; 320(19): 1238–43CrossRefGoogle Scholar
  60. 60.
    Pommer W, Bronder E, Greiser E, et al. Regular analgesic intake and the risk of end-stage renal failure. Am J Nephrol 1989; 9(5): 403–12PubMedCrossRefGoogle Scholar
  61. 61.
    Morlans M, Laporte JR, Vidal X, et al. End-stage renal disease and non-narcotic analgesics: a case-control study. Br J Clin Pharmacol 1990; 30(5): 717–23PubMedCrossRefGoogle Scholar
  62. 62.
    Steenland NK, Thun MJ, Ferguson CW, et al. Occupational and other exposures associated with male end-stage renal disease: a case/control study [see comments]. Am J Public Health 1990; 80(2): 153–7PubMedCrossRefGoogle Scholar
  63. 63.
    Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs [see comments]. N Engl J Med 1994; 331(25): 1675–9PubMedCrossRefGoogle Scholar
  64. 64.
    Dubach UC, Rosner B, Sturmer T. An epidemiologic study of abuse of analgesic drugs: effects of phenacetin and salicylate on mortality and cardiovascular morbidity (1968 to 1987) [see comments]. N Engl J Med 1991; 324(3): 155–60PubMedCrossRefGoogle Scholar
  65. 65.
    Elseviers MM, De Broe ME. A long-term prospective controlled study of analgesic abuse in Belgium. Kidney Int 1995; 48(6): 1912–9PubMedCrossRefGoogle Scholar
  66. 66.
    Garattini S. Caffeine, caffee and health. New York (NY): Raven Press, 1993Google Scholar
  67. 67.
    Brezis M, Rosen S, Epstein FH. The pathophysiological implications of medullary hypoxia. Am J Kidney Dis 1989; 13(3): 253–8PubMedGoogle Scholar
  68. 68.
    Bennett WM, De Broe ME. Analgesic nephropathy: a preventable renal disease. N Engl J Med 1989; 320: 1269–71PubMedCrossRefGoogle Scholar
  69. 69.
    Lehmann H, Hirsch U, Bauer E, et al. Studies on the chronic oral toxicity of an analgesic drug combination consisting of acetylsalicylic acid, paracetamol and caffeine in rats including an electron microscopical evaluation of kidneys. Arzneimittel-Forschung/Drug Res 1996; 46: 895–905Google Scholar
  70. 70.
    Cronin RE, Heinrich WL. Toxic nephropathy. In: Brenner BM, Rector FC, editors. Brenner & Rector’s the kidney. 5th ed. Philadelphia (PA): Saunders, 1996: 1680–711Google Scholar
  71. 71.
    Dews PB, Curtis GL, Handford KJ, et al. The frequency of caffeine withdrawal in a population-based survey and in a controlled blinded experiment. J Clin Pharmacol 1999: 12Google Scholar
  72. 72.
    Shuh KJ, Griffiths RR. Caffeine reinforcement: the role of withdrawal. Psychopharmacology 1997; 130: 320–6CrossRefGoogle Scholar

Copyright information

© Adis international Limited 2001

Authors and Affiliations

  1. 1.Centre for Evidence-Based Pharmacotherapy, Pharmaceutical Sciences, Aston UniversityBirminghamUK

Personalised recommendations